LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Want to cut your energy bills? Here’s how five experts are doing it 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
SOUTH SAN FRANCISCO, Calif., March 08, 2017 -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that it will present a company overview at the 29th Annual ROTH Conference taking place from March 12-15, 2017 in Dana Point, California.
Mateon’s management will present a company overview on Wednesday, March 15, 2017 at 7:30 am pacific time. A live webcast of the presentation will be available on the company’s website at www.mateon.com in “Events & Presentations” under the “Investors & News” tab. A replay of the webcast will be available approximately one hour following the completion of the live event.
About Mateon
Mateon Therapeutics, Inc. is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action.
At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.
Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.
CONTACTS Investors: PCG Advisory Group Stephanie Prince, Managing Director [email protected] 646-762-4518 Media: JPA Health Communications Nic DiBella [email protected] 617-945-5183
